Theranexus (ALTHX.PA) Osake Kurssi
Theranexus Kurssi
Liikevaihto on kasvanut 16,9 % vuodessa viimeisten 9 vuoden aikana 2,28 M EUR:een. Theranexusn nettomarginaali on nyt −77,3 %, noussut −1 628,5 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 4,49 EUR, eli yli nykyhintaa 35,0 %. 9 analyytikosta 8 suosittaa ostoa — kokonaiskonsensus on Osta.
Theranexus osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Theranexus liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Theranexus -osakkeesta
The business model of Theranexus SA revolves around the development and commercialization of innovative therapeutic solutions for neurological disorders. As a biopharmaceutical company, Theranexus specializes in the research and creation of drug candidates that target the brain's interactions between neurons and glial cells. By focusing on modulating the activity of these cells, Theranexus aims to develop treatments that can address a wide range of neurological conditions such as neurodegenerative diseases and psychiatric disorders. Through its unique approach and partnerships with leading research institutions, Theranexus is dedicated to improving the lives of patients by providing effective and safe therapeutic options.
Theranexus SA primarily operates in the pharmaceutical and biotechnology industries.
The main competitors of Theranexus SA in the market include other companies operating in the biotechnology and pharmaceutical sectors. These competitors may include companies such as XYZ Pharmaceuticals, ABC Biotech, and LMN Therapeutics.
Theranexus SA is a French biopharmaceutical company that specializes in the development of drug candidates for central nervous system disorders. Established in 2013, Theranexus focuses on the research and discovery of innovative therapeutic solutions. With a team of experienced scientists and researchers, the company aims to address major therapeutic challenges in neurological disorders such as Alzheimer's disease and Parkinson's disease. Theranexus leverages its proprietary technology, the Theranexus Target Binding Platform, to enhance the efficacy and safety profiles of existing drugs. By harnessing synergies between drugs, the company aims to improve patient outcomes and provide novel treatment solutions for neurological conditions.
Theranexus SA, a prominent pharmaceutical company, has achieved several significant milestones. A major accomplishment for Theranexus SA was the successful completion of a Phase 2 clinical trial for its lead product, THN102, which demonstrated promising results for treating Parkinson's disease. Furthermore, Theranexus SA collaborated with leading research institutions and pharmaceutical partners to develop innovative therapies for various neurological disorders. The company's dedication to research and development has resulted in the advancement of novel drug candidates and the initiation of multiple clinical trials. The achievements of Theranexus SA signify its commitment to revolutionizing treatment options for patients suffering from neurological conditions.
Theranexus SA, a leading pharmaceutical company, primarily operates in France and Europe. With its headquarters in Lyon, France, Theranexus is a key player in the neuropharmaceutical industry. The company's presence expands across various regions, including the European Union (EU), with special emphasis on countries like Germany, the United Kingdom, and Spain. Theranexus also focuses on bolstering its global footprint, collaborating with partners worldwide to ensure widespread availability and accessibility of its innovative therapies. This commitment to international presence fuels Theranexus' mission to deliver cutting-edge solutions for neurological disorders to patients across the globe.
Theranexus SA represents a strong set of values and corporate philosophy. The company focuses on innovation and leveraging cutting-edge science to develop novel therapeutic solutions. Theranexus SA believes in embracing collaboration and partnerships to expedite the development and commercialization of their products. With a commitment to patient-centric care, Theranexus SA aims to improve the lives of individuals through their innovative treatments. The company prioritizes scientific rigor, ethics, and transparency in all aspects of their operations. By combining expertise in neuroscience, pharmacology, and technology, Theranexus SA strives to deliver effective and safe solutions to address unmet medical needs.
Analyytikot asettavat tällä hetkellä Theranexus-osakkeelle keskimääräisen tavoitehinnan 4,49 EUR (mediaani: 4,49 EUR), mikä merkitsee +35,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 9 analyytikkoarvioon.
9 analyytikkoa arvioi tällä hetkellä Theranexus-osaketta: 8 suosittaa ostoa, 1 pitoa ja 0 myyntiä.
Theranexus-osake (ALTHX.PA) on listattuna 4 pörssissä, muun muassa: Frankfurt (3VG.F), München (3VG.MU), Paris (ALTHX.PA).
Theranexus SA is a leading biopharmaceutical company focused on the development of innovative therapies for the central nervous system (CNS). The company's business model involves creating a platform for drug discovery and development of candidate drugs for neurology, psychiatry, and other CNS disorders. Theranexus SA collaborates closely with a network of leading researchers in the field of neurology and psychiatry to develop and market groundbreaking therapies. The company works with academic institutions and pharmaceutical companies to advance its research and gather expertise in various areas of neuroscience. Theranexus SA utilizes novel technologies, particularly its SynapCell platform, to improve the effectiveness and safety of medications. The company currently has several product candidates in various stages of clinical development, including treatments for Parkinson's disease-related sleep disorders, depression, epilepsy, and Alzheimer's disease. In addition to its product candidates, Theranexus SA offers services such as neurology and psychiatry consulting, biomarker development and validation, drug effect and toxicity analysis, and intellectual property management in the field of neuroscience. Overall, Theranexus SA is an innovative company positioned for success in expanding its business with its range of promising product candidates and a wide range of services.
Liikevaihtoa ei voida laskea Theranexus:lle tällä hetkellä.
odotettu voitto Theranexus on 1,66 M EUR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Theranexus:n hinta-voitto-suhde (P/E) on tällä hetkellä 27,57. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Theranexus-osakkeen arvostusta.
P/S-suhdetta ei voida laskea Theranexus:lle tällä hetkellä.
Theranexus:n Eulpool-laatuscore on 2/10.
Theranexus:n ISIN on FR0013286259. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Theranexus:n WKN on A2H6LX. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Theranexus:n ticker on ALTHX.PA. Tämä pörssinoteeraus käytetään Theranexus-osakkeiden kauppaan pörssissä.
Theranexus osake
Theranexus vertaisryhmä
Theranexus Ticker
Theranexus FIGI
Kaikki tunnusluvut ja syvällinen analyysi Theranexus:sta
Meidän osakeanalyysimme Theranexus-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Theranexus:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: